SANOFI-ADR (SNY) Stock Fundamental Analysis
USA - NASDAQ:SNY - US80105N1054 - ADR
50.14 USD
+1.18 (+2.41%)
Taking everything into account, SNY scores 6 out of 10 in our fundamental rating. SNY was compared to 195 industry peers in the Pharmaceuticals industry. While SNY has a great profitability rating, there are some minor concerns on its financial health. SNY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. Finally SNY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year SNY was profitable.
In the past year SNY had a positive cash flow from operations.
SNY had positive earnings in each of the past 5 years.
Each year in the past 5 years SNY had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 11.05%, SNY belongs to the best of the industry, outperforming 92.82% of the companies in the same industry.
SNY's Return On Equity of 19.73% is amongst the best of the industry. SNY outperforms 92.31% of its industry peers.
With an excellent Return On Invested Capital value of 13.84%, SNY belongs to the best of the industry, outperforming 92.31% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for SNY is significantly below the industry average of 15.30%.
The 3 year average ROIC (7.31%) for SNY is below the current ROIC(13.84%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROIC | 13.84% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
1.3 Margins
With an excellent Profit Margin value of 20.35%, SNY belongs to the best of the industry, outperforming 93.85% of the companies in the same industry.
In the last couple of years the Profit Margin of SNY has grown nicely.
With an excellent Operating Margin value of 23.59%, SNY belongs to the best of the industry, outperforming 90.26% of the companies in the same industry.
SNY's Operating Margin has improved in the last couple of years.
The Gross Margin of SNY (71.70%) is better than 77.95% of its industry peers.
SNY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% |
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
SNY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
SNY has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for SNY remains at a similar level compared to 5 years ago.
Compared to 1 year ago, SNY has an improved debt to assets ratio.
2.2 Solvency
The Debt to FCF ratio of SNY is 2.21, which is a good value as it means it would take SNY, 2.21 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.21, SNY belongs to the best of the industry, outperforming 92.82% of the companies in the same industry.
A Debt/Equity ratio of 0.21 indicates that SNY is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.21, SNY perfoms like the industry average, outperforming 45.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Altman-Z | N/A |
ROIC/WACC1.88
WACC7.37%
2.3 Liquidity
SNY has a Current Ratio of 1.27. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.27, SNY is not doing good in the industry: 74.87% of the companies in the same industry are doing better.
SNY has a Quick Ratio of 1.27. This is a bad value and indicates that SNY is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of SNY (0.94) is worse than 75.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
The earnings per share for SNY have decreased by -2.20% in the last year.
The Earnings Per Share has been growing slightly by 5.10% on average over the past years.
The Revenue has been growing slightly by 6.45% in the past year.
The Revenue has been growing slightly by 3.31% on average over the past years.
EPS 1Y (TTM)-2.2%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%-8.09%
Revenue 1Y (TTM)6.45%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-6.99%
3.2 Future
The Earnings Per Share is expected to grow by 6.84% on average over the next years.
The Revenue is expected to grow by 4.46% on average over the next years.
EPS Next Y4.12%
EPS Next 2Y6.3%
EPS Next 3Y6.57%
EPS Next 5Y6.84%
Revenue Next Year-0.42%
Revenue Next 2Y3.06%
Revenue Next 3Y4.26%
Revenue Next 5Y4.46%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SNY is valuated reasonably with a Price/Earnings ratio of 11.37.
89.74% of the companies in the same industry are more expensive than SNY, based on the Price/Earnings ratio.
SNY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.53.
The Price/Forward Earnings ratio is 9.88, which indicates a very decent valuation of SNY.
85.64% of the companies in the same industry are more expensive than SNY, based on the Price/Forward Earnings ratio.
SNY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.04.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.37 | ||
| Fwd PE | 9.88 |
4.2 Price Multiples
SNY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SNY is cheaper than 97.44% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SNY is valued cheaper than 90.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.44 | ||
| EV/EBITDA | 5.59 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of SNY may justify a higher PE ratio.
PEG (NY)2.76
PEG (5Y)2.23
EPS Next 2Y6.3%
EPS Next 3Y6.57%
5. Dividend
5.1 Amount
SNY has a Yearly Dividend Yield of 4.62%, which is a nice return.
SNY's Dividend Yield is rather good when compared to the industry average which is at 6.60. SNY pays more dividend than 95.90% of the companies in the same industry.
SNY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.62% |
5.2 History
The dividend of SNY has a limited annual growth rate of 4.30%.
SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of SNY decreased in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
34.82% of the earnings are spent on dividend by SNY. This is a low number and sustainable payout ratio.
The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP34.82%
EPS Next 2Y6.3%
EPS Next 3Y6.57%
NASDAQ:SNY (10/16/2025, 11:43:06 AM)
50.14
+1.18 (+2.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners47.5%
Inst Owner Change-0.01%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap122.19B
Analysts81.38
Price Target63.76 (27.16%)
Short Float %0.23%
Short Ratio1.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.62% |
Yearly Dividend2.2
Dividend Growth(5Y)4.3%
DP34.82%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.86%
Min EPS beat(2)-2.29%
Max EPS beat(2)6.02%
EPS beat(4)2
Avg EPS beat(4)4.01%
Min EPS beat(4)-2.29%
Max EPS beat(4)14.5%
EPS beat(8)4
Avg EPS beat(8)2.17%
EPS beat(12)7
Avg EPS beat(12)2.71%
EPS beat(16)11
Avg EPS beat(16)3.44%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.12%
Revenue beat(12)4
Avg Revenue beat(12)9.26%
Revenue beat(16)8
Avg Revenue beat(16)21.08%
PT rev (1m)0.07%
PT rev (3m)-2.53%
EPS NQ rev (1m)-0.12%
EPS NQ rev (3m)-6.56%
EPS NY rev (1m)0.28%
EPS NY rev (3m)-4.6%
Revenue NQ rev (1m)-0.21%
Revenue NQ rev (3m)-2.05%
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)-1.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.37 | ||
| Fwd PE | 9.88 | ||
| P/S | 1.55 | ||
| P/FCF | 10.44 | ||
| P/OCF | 9.24 | ||
| P/B | 1.5 | ||
| P/tB | 11.31 | ||
| EV/EBITDA | 5.59 |
EPS(TTM)4.41
EY8.8%
EPS(NY)5.07
Fwd EY10.12%
FCF(TTM)4.8
FCFY9.58%
OCF(TTM)5.43
OCFY10.82%
SpS32.38
BVpS33.39
TBVpS4.43
PEG (NY)2.76
PEG (5Y)2.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROCE | 16.7% | ||
| ROIC | 13.84% | ||
| ROICexc | 16.48% | ||
| ROICexgc | 66.95% | ||
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% | ||
| FCFM | 14.83% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
ROICexc(3y)8.13%
ROICexc(5y)7.97%
ROICexgc(3y)35.39%
ROICexgc(5y)35.54%
ROCE(3y)8.84%
ROCE(5y)8.55%
ROICexcg growth 3Y-13.63%
ROICexcg growth 5Y-1.43%
ROICexc growth 3Y-1.55%
ROICexc growth 5Y2.05%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Debt/EBITDA | 0.75 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 58.05% | ||
| Profit Quality | 72.91% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | N/A |
F-Score7
WACC7.37%
ROIC/WACC1.88
Cap/Depr(3y)73.02%
Cap/Depr(5y)67.36%
Cap/Sales(3y)6.35%
Cap/Sales(5y)5.97%
Profit Quality(3y)113.82%
Profit Quality(5y)104.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.2%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%-8.09%
EPS Next Y4.12%
EPS Next 2Y6.3%
EPS Next 3Y6.57%
EPS Next 5Y6.84%
Revenue 1Y (TTM)6.45%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-6.99%
Revenue Next Year-0.42%
Revenue Next 2Y3.06%
Revenue Next 3Y4.26%
Revenue Next 5Y4.46%
EBIT growth 1Y15.64%
EBIT growth 3Y1.33%
EBIT growth 5Y5.12%
EBIT Next Year30.73%
EBIT Next 3Y13.89%
EBIT Next 5Y9.93%
FCF growth 1Y24.23%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y10.87%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%